Tissue Analytics, with their launch of an EHR-Interoperable Marketplace for wound care diagnostic and preventive devices, announces collaborative partnership with Kent Imaging.

This partnership allows physicians to quickly and easily assess tissue viability and track wound healing progression when advanced wound care therapies are applied. Kent’s CEO, Pierre Lemire, is states “An open API from Tissue Analytics provides a key framework where tissue oxygenation images captured with SnapshotNIR can be combined with wound data from other vendors to enhance wound comprehension and impact decision making. This improves the clinically relevant data that is required to assess and manage wounds.” 

Tissue-Analytics-Kent-Imaging-PR

Kent Imaging Inc. and Synchrocare, LLC announce an agreement that provisions Synchrocare, LLC with the distribution of Kent Imaging’s innovative new medical device SnapshotNIR.

SnapshotNIR utilizes near infrared light to assess oxygenated and deoxygenated hemoglobin providing an assessment of tissue oxygenation at all points of care in wounds, limb salvage, vascular, and flap based reconstructive surgery. 

Synchrocare-LLC-announcement-v3

Perry Baromedical and Kent Imaging Inc. announce Strategic Partnership in Hyperbarics

RIVIERA BEACH, Florida, July 17, 2018 (CSN) — Perry Baromedical and Kent Imaging Inc. today announced a Strategic Partnership where Perry will distribute Kent’s Near Infrared Imaging device (SnapshotNIR).

Through this partnership, Perry Baromedical, the only full line manufacturer of hyperbaric chambers in the industry, will continue to extend the innovative solutions that it offers its customers.  Kent’s tissue assessment technology is easy to use, convenient, and provides a cost-effective method of assessing the effects of hyperbaric therapy on wound oxygenation and wound health thus supporting the course of treatment and continuing to build the value Perry brings to its customers.

Oxygenation is widely accepted as the best biomarker of tissue health and healing.  Kent’s device is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports oxygen saturation (StO2), relative oxyhemoglobin level (HbO2), and relative deoxyhemoglobin (Hb) level in superficial tissue. Kent’s NIR multispectral imaging technology displays two-dimensional color-coded images providing critical information to help clinicians determine at risk tissue and guide treatments optimizing patient outcomes in wound care, plastic surgery, and various other reconstructive applications.

“Perry is pleased with our partnership with Kent as it represents the best of multi-spectral imaging technology available.  Our collective commitment to the industry is to offer best of class products with ease of use to our end users and a non-invasive technology for the patients.” Perry President and COO Mary Pat Finn enthusiastically stated.  “The Kent partnership allows Perry to offer essential comprehensive technology to enhance the diagnostic offerings in the wound care and hyperbaric market.”

“This partnership with Perry further optimizes patient treatment and monitoring resulting in better patient outcomes while helping reduce costs to the medical system” said Pierre Lemire, CEO of Kent Imaging.  “We are thrilled to bring together the leading-edge treatment technologies of Perry with the advanced tissue assessment technology of Kent – the winners are the patients, staff, and overall health care system.  This partnership with Perry aligns with Kent’s goal to lower complications and reduce the cost of care in wound healing.”

Features of Kent’s Tissue Oxygenation Assessment device:

  • Cordless handheld portable for use in all care setting
  • Instant tissue assessment
  • Non-invasive with no injectables or dyes
  • A means to track patient progress and treatment effectiveness
  • Provides quantified tissue oxygenation levels
  • No disruption to existing workflow
  • Accurate, unlimited imaging and storage
  • Ease-of-use with minimal training required
  • Low cost device with no disposables or pay per click fees

Kent has received all necessary clearances for product sales in the United States, Canada, and Europe.

About Perry Baromedical

Perry Baromedical Corporation is dedicated to providing the highest quality hyperbaric chambers, EMR software, services and educational programs in the industry. Expertise in advanced engineering technology, software development along with proprietary manufacturing process and global resources, allow us to produce, ship, install, service, and offer education worldwide. Perry Baromedical is the only US hyperbaric chamber manufacturer that builds three acrylic monoplace models, dual place, and multi place units including the largest acrylic monoplace hyperbaric chamber in the world. For more information please visit www.perrybaromedical.com or call 1-800-741-4376.

About Kent Imaging Inc.

Kent Imaging, located in Calgary, Alberta, Canada, is a leading developer of medical technology, who imagines, designs, manufactures and markets imaging technology for wound and surgical care. Kent holds multiple patents in medical technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about the company visit www.kentimaging.com.

For further information, please contact:

Perry Baromedical, Sharon Marshall – Corp Communication.

Email: smarshall@perryhbo.com Phone 800.741.4376

Kent Imaging Inc., Jeff Hydar – VP Sales

Email: jhydar@kentimaging.com Phone: 403.455.7610

Kent Imaging Inc. and SerenaGroup announce Strategic Partnership in wound care

CALGARY, Alberta, Canada, June 27, 2018 /CNW/ – Kent Imaging Inc. and SerenaGroup® today announced a Strategic Partnership to jointly improve tissue assessment in wounds with the use of Near Infrared Imaging technology using Kent’s SnapshotNIR device.

Oxygenation is widely accepted as the best biomarker of tissue health and healing.  Kent’s device is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports oxygen saturation (StO2), relative oxyhemoglobin level (HbO2), and relative deoxyhemoglobin (Hb) level in superficial tissue. Kent’s multispectral imaging technology displays two-dimensional color-coded images providing critical information to help clinicians determine at risk tissue and guide treatments to optimize patient outcomes in wound care, plastic surgery, and various other reconstructive applications.

This is a great partnership between one of the leaders in building wound care teams and an innovative tissue assessment technology that is easy to use, convenient, and cost effective. SerenaGroup® will adopt Kent Imaging’s technology as the standard of care for assessing wound oxygenation thus wound health.  Kent will be integrated into each of the SerenaGroup® managed facilities, included in Hyperbaric training courses curriculum, as well as included in future clinical and preclinical research.

“We are pleased to introduce Kent’s imaging system into the wound care protocol at our clinics. One of the most troublesome and elusive criteria in treating wounds is the timely and accurate assessment of viable tissue.” said Dr. Serena MD FACS FACHM MAPWCA, Founder and Medical Director of The SerenaGroup®.  “Kent’s device will propel us a long way down the healing path with a technology that has been lacking across the board in the Wound Care space. ”

“Our joint belief is that we can improve patient care and outcomes by significantly improving clinically relevant data that is required to assess and manage wounds.” added Pierre Lemire, CEO of Kent Imaging.  “We are excited to be partnering with SerenaGroup and with Dr. Serena who has dedicated his career to improving patient outcomes in wound care.”

Features of Kent’s Tissue Oxygenation Assessment device:

  • Cordless handheld portable for use in all care setting
  • Instant tissue assessment
  • Non-invasive with no injectables or dyes
  • A means to track patient progress and treatment effectiveness
  • Provides quantified tissue oxygenation levels
  • No disruption to existing workflow
  • Accurate, unlimited imaging and storage
  • Ease-of-use with minimal training required
  • Low cost device with no disposables or pay per click fees

Kent is available for sale in the United States, Canada, and Europe with FDA Class II clearance, Health Canada clearance, and CE Mark.

About Kent Imaging Inc.
Kent Imaging, located in Calgary, Alberta, Canada, is a leading developer of medical technology, who imagines, designs, manufactures and markets imaging technology for wound and surgical care. Kent holds multiple patents in medical technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about the company visit www.kentimaging.com.

About SerenaGroup, Inc.
SerenaGroup® is the leader in wound healing research worldwide. Under the leadership of Dr. Serena, the organization has conducted over 100 clinic trials in collaboration with the nation’s first wound healing cooperative group. SerenaGroup® continues to expand its offerings to include interrelated technology solutions.  SerenaGroup® is a global health care management company with the mission to develop the world’s leading centers of excellence in wound and hyperbaric medicine. SerenaGroup® has placed a special emphasis on clinical performance, outcomes and clinical research in the wound care space. For more information about the company visit www.serenagroups.com

Kent Imaging Inc.: Jeff Hydar – VP Sales, jhydar@kentimaging.com, Phone: 403.455.7610 SerenaGroup®: Anthony Serena – COO, easerena@serenagroups.com, Phone: 617.945.5225

Kent Imaging, Inc. Announces CE Mark for New Multispectral Imaging Product, Kent’s SnapshotNIR

CALGARY, Alberta, Canada, May 30, 2018 (CNW) — Kent Imaging, a leading provider of near infrared imaging solutions, announced today that it has received CE Mark approval for the Kent multispectral Medical Imaging Device (SnapshotNIR).  The Kent device is also listed as a Class II medical device with US FDA and Health Canada.  This now allows Kent to expand its markets with distribution in Europe.

Kent Imaging has been working with European Research partners for the past 6 years to gather and publish clinical results using the Kent Device.

“Translational research is the word of the time.” Said Dr. Flavio Coceani, Scuola Superiore Sant’Anna in Pisa, Italy.  “Kent embodies this hallmark inasmuch as it moves an idea from the bench to the medical practice in a simple, cost-effective format.”

Kent Imaging’s device is the newest advancement in tissue oxygenation and perfusion imaging. The imaging device is handheld, cordless, portable, non-invasive and eliminates the need for tissue contact or injection of dyes. The Kent device operates with similar speed to a point and shoot camera and provides insight into the availability of oxygenated blood in tissue. This enables rapid and improved decision-making throughout the dynamic treatment path and helping to avoid unnecessary complications or corrections across the multiple points of care.

“We are very excited about obtaining CE Mark for our handheld device.”, said Pierre Lemire, CEO of Kent Imaging. “This is another key milestone in Kent’s growth strategy.  We can now engage with our European partners to bring our innovative technology to the European medical community.”

The Kent device has gained acceptance in both flap and implant-based reconstruction, abdominal wall surgery, colorectal surgery, cardiac use, vascular surgery, and various types of wound care. The Kent device is available for use in the operating room, clinics, and other care settings.

About Kent Imaging Inc.

Kent Imaging is an innovative healthcare technology company who imagines, designs, prototypes, commercializes and manufactures spectral imaging solutions for the medical industry. Kent’s products provide low cost non-invasive diagnostic insight into tissue health to aid healthcare personnel to provide the best possible care for patients.  For more information about our company visit us at www.kentimaging.com.

For further information, please contact: Kent Imaging Inc.

Katelyn Oldale – Marketing Manager E-mail: katelyn@kentimaging.com Phone: 1-403.455-7610

Kent Imaging Announces Strategic Partnership to Advance Tissue Assessment

CALGARY, March 20, 2018 –Kent Imaging Inc. announced today a strategic relationship with Allergan Canada to advance tissue assessment in Canada.

This opportunity adds the Kent device to Allegan Canada’s Medical Aesthetics division with another solution for breast augmentation surgery along with AlloDerm®, Natrelle®, Revolve®, and the Keller Funnel®.

The Kent device is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports oxygen saturation (StO2), relative oxyhemoglobin level (HbO2), and relative deoxyhemoglobin (Hb) level in superficial tissue. Kent’s multispectral imaging technology displays two-dimensional colour-coded images providing critical information to help physicians determine at risk tissue and guide treatments to optimize patient outcomes in breast, reconstructive, and various other plastic surgery applications.

“With the Kent device, we can quantify oxygenation which is the best biomarker for tissue health and predictor of tissue viability in creating flaps with surgically reconstructed patients,” said Carmen Enciu, Medical Director and Head of the Canadian Chief Medical Office. This opportunity further reinforces Allergan Canada’s commitment to patients in need of treatment by finding innovative technologies that improve outcomes.”

“We are very excited about this strategic partnership”, said Pierre Lemire, CEO of Kent Imaging. “Working with Allergan Canada, we can help physicians determine the most effective treatment plans which provides them a means of reducing recovery times and patient discomfort, as well as optimizing patient outcomes.”

Features of Kent’s Tissue Oxygenation Assessment device:

  • Cordless handheld portable for use in all care setting
  • Instant tissue assessment
  • Non-invasive with no injectables or dyes
  • A means to track patient progress and treatment effectiveness
  • Provides quantified tissue oxygenation levels
  • No disruption to existing workflow
  • Accurate, unlimited imaging and storage
  • Ease-of-use with minimal training required
  • Low cost device with no disposables or pay per click fees

Kent is now available for sale in both the United States and Canada.

About Kent Imaging Inc.

Kent Imaging, located in Calgary, Alberta, Canada, is a leading developer of medical technology, who designs, manufactures and markets imaging technology for wound and surgical care. Kent holds multiple patents in medical technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about our company visit us at www.kentimaging.com.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.

Allergan’s success is powered by our global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan’s website at www.allergan.com

For further information: Media Inquiries: Jeff Hydar, Kent Imaging, jhydar@kentimaging.com, 630.746.2218; Liana Del Medico, Allergan Canada, MR-Canada_Communications@Allergan.com, 905-940-7327

Kent Imaging’s Breakthrough Medical Imaging Device Licensed with Health Canada

CALGARY, Nov. 7, 2017 /CNW/ – Kent Imaging Inc., a leading innovator in multispectral oxygenation imaging, announced today that their handheld SnapshotNIR is a licensed medical device with Health Canada. Kent’s device is also cleared with the U.S. Food and Drug Administration (FDA) and the company is ISO13485 certified.

Kent’s handheld SnapshotNIR measures and displays quantified tissue oxygen saturation levels in superficial tissue. Tissue oxygen saturation measurements provide critical information to help physicians determine at risk tissue and guide treatments to optimize patient outcomes. Kent’s easy to use device is available for sale in the United States and Canada with utility in plastic surgery, colorectal surgery, trauma, wound care, limb salvage, podiatry, burns and cardiac specialties.

“The Kent Imaging camera is unique in its ability to assess oxygenation in tissue using spectroscopy,” said Dr. Earl Campbell MD, FRCSC, practicing surgeon and a member of the Alberta Medical Association and the Canadian Society of Plastic Surgeons. “Plastic surgeons in Calgary, Alberta are already exploring its intra-operative uses when performing breast reconstruction procedures.”

“We are happy to announce our licence with Health Canada,” said Pierre Lemire, CEO of Kent Imaging. “This, along with its FDA clearance, has made our handheld device, the SnapshotNIR, readily available to the physicians and surgeons who require the valuable insight it provides.”

Features of Kent’s SnapshotNIR:

  • Instant and precise visualization of oxygen saturation
  • Non-invasive with no injectable dyes
  • Ability to image the actual wound bed and surrounding tissue
  • Oxygenation measurement of surgical sites or reconstructive flaps
  • A means to track patient progress and treatment effectiveness
  • Ease-of-use with minimal training required
  • Accurate, unlimited imaging
  • Lightweight and completely portable handheld device

About Kent Imaging Inc.
Kent Imaging Inc., a leading innovator in multispectral oxygenation imaging, designs, manufactures, and markets imaging technology to improve health care. The team at Kent Imaging is committed to improving patient outcomes by delivering innovative and practical solutions for the healthcare industry. Kent Imaging holds multiple patents in medical technology and is currently commercializing the breakthrough multispectral imaging solutions that assesses tissue oxygen saturation. The company is headquartered in Calgary, Alberta, Canada, and has locations in Chicago, Los Angeles, Salt Lake City and Seattle.

Kent’s SnapshotNIR is U.S. Food and Drug Administration 510(k) cleared, and Health Canada licensed. The device is available for sale in the United States and Canada. Improving on Kent’s previous KC103, the handheld Kent SnapshotNIR is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports oxygen saturation (StO2), relative oxyhemoglobin level (HbO2), and relative deoxyhemoglobin (Hb) level in superficial tissue. Kent’s multispectral imaging technology displays two-dimensional color-coded images of tissue oxygenation of the scanned surface and reports multispectral tissue oxygenation measurements for selected tissue regions. Tissue oxygen saturation measurements provide critical information to help physicians determine at risk tissue and guide treatments to optimize patient outcomes.

Jeff Hydar Joins Kent Imaging as Vice President of Sales, USA

Jeff Hydar is an award winning strategic sales executive who has run successful teams throughout the United States. Hydar’s experience guiding sales teams and his motivational leadership style will propel Kent’s product sales in the wound and surgical care market.

Hydar’s sales leadership enables Kent Imaging to further scale and grow.                 

CALGARY, Nov. 1, 2017 /CNW/ – Kent Imaging Inc. a leading innovator in multispectral oxygenation imaging, today announced Jeff Hydar as the new Vice President of Sales, USA. Jeff Hydar is an award winning strategic sales executive who has run successful teams throughout the United States. Hydar’s experience guiding sales teams and his motivational leadership style will propel Kent’s product sales in the wound and surgical care market.

“With Kent’s recent FDA clearance of the SnapshotNIR, we have a significant opportunity to simplify the way physicians and surgeons assess, care for, and monitor acute and chronic wounds or surgically reconstructed tissue.” said Jeff Hydar. “Multispectral imaging is enabling a new generation of tools that use tissue oxygenation measurements to assess tissue viability. I’m very excited to help introduce this new technology into the market.”

“Jeff brings over twenty years of pharmaceutical and medical device sales and leadership experience to Kent. His exceptional background and relationships in plastic surgery, colorectal surgery, trauma, wound care, limb salvage, podiatry, burns and cardiac specialties are strong additions to the Kent team.” said Pierre Lemire, CEO of Kent Imaging.

Hydar’s prior experience with Johnson & Johnson, LifeCell (Acelity), and Medline has been focused on launching various new medical technologies and devices.

About Kent Imaging Inc.
Kent Imaging, a leading innovator in multispectral oxygenation imaging, designs, manufactures, and markets imaging technology to improve health care. Headquartered in Calgary, Canada, Kent holds multiple patents in medical technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally.

Kent’s SnapshotNIR is U.S. Food and Drug Administration 510(k) cleared, and Health Canada licensed. The device is available for sale in the United States and Canada. Improving on Kent’s previous KC103, the handheld Kent SnapshotNIR is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports oxygen saturation (StO2), relative oxyhemoglobin level (HbO2), and relative deoxyhemoglobin (Hb) level in superficial tissue. Kent’s multispectral imaging technology displays two-dimensional color-coded images of tissue oxygenation of the scanned surface and reports multispectral tissue oxygenation measurements for selected tissue regions. Tissue oxygen saturation measurements provide critical information to help physicians determine at risk tissue and guide treatments to optimize patient outcomes.

Kent Imaging Inc., www.kentimaging.com, Vonda-Lee Sharun – Marketing Manager, press@kentimaging.com

Kent Imaging Revolutionizes Perfusion Imaging with Their FDA Cleared SnapshotNIR

CALGARY, Oct. 19, 2017 /CNW/ – Kent Imaging, a leading provider of near infrared imaging solutions, announced today that the U.S. Food and Drug Administration (FDA) has cleared their multispectral Medical Imaging Device (SnapshotNIR).

Kent’s device is the next step in perfusion imaging by directly showing tissue oxygenation. The SnapshotNIR provides insight into the availability of oxygenated blood in tissue, which enables accurate diagnosis, improved treatment planning and effective patient monitoring.

“Using the Kent camera, we can quantify perfusion directly by determining the ratio of oxygenated to deoxygenated hemoglobin”, said Dr. Adam Landsman, DPM, PhD, Chief of Division of Podiatric Surgery at the Cambridge Health Alliance (Harvard Medical School). Furthermore, because the data can be collected in less than a second, the device can help to quantify the effect of our treatments, and allow us to easily monitor the patient’s condition on a regular basis.”

“We are very excited about obtaining Class II FDA clearance for our handheld device”, said Pierre Lemire, CEO of Kent Imaging. “Our low cost and easy to use device helps physicians to determine the most effective treatment plans which provides them a means of reducing recovery times and patient discomfort.”

Features of Kent’s SnapshotNIR:

  • Instant wound assessment
  • Non-invasive with no injectables or dyes
  • A means to track patient progress and treatment effectiveness
  • Provides quantified tissue oxygenation levels
  • No disruption to existing workflow
  • Accurate, unlimited imaging and storage
  • Ease-of-use with minimal training required
  • Low cost device with no disposables
  • Lightweight portable handheld device

The SnapshotNIR is now available for sale in both the United States and Canada.

About Kent Imaging Inc.

Kent Imaging, located in Calgary, Alberta, Canada, is a leading developer of medical technology, who designs, manufactures and markets imaging technology for wound and surgical care. Kent holds multiple patents in medical technology and continues to provide innovative and advanced diagnostic imaging solutions to aid healthcare systems nationally and internationally. For more information about our company visit us at www.kentimaging.com.

Kent Imaging Inc., Vonda-Lee Sharun – Marketing Manager, press@kentimaging.com, Phone: 1.403.605.0230

Kent Imaging Receives ISO 13485 Certification

Kent Imaging announced today that it has passed the ISO 13485 requirements for a comprehensive quality management system for the design and manufacture of medical devices. This new certification marks another key milestone in Kent’s continuous improvement strategy. It demonstrates Kent’s commitment to quality and customer satisfaction. Achieving this level of certification allows Kent to pursue additional regulatory clearances for its medical imaging device including Health Canada clearance.